Related Experiment Videos
Enhancement of visit adherence in the national beta-blocker heart attack trial
Insights
The Beta Blocker Heart Trial (BHAT) improved patient visit adherence in post-myocardial infarction (MI) patients through various compliance strategies. This secondary prevention trial demonstrated high adherence rates, exceeding those in comparable studies.
Area of Science:
- Cardiology
- Clinical Trials
- Public Health
Background:
- Patient adherence is crucial for the success of clinical trials, particularly in secondary prevention after myocardial infarction (MI).
- Monitoring visit adherence provides an objective measure of compliance, distinct from subjective patient self-reporting.
- The Beta Blocker Heart Trial (BHAT) aimed to optimize adherence in a large cohort of post-MI individuals.
Purpose of the Study:
- To implement and evaluate strategies for enhancing patient visit adherence in the Beta Blocker Heart Trial (BHAT).
- To assess the overall adherence rates and identify patient dropout/loss to follow-up in a large-scale secondary prevention trial.
Main Methods:
- The study involved 3837 post-MI patients in a double-blind design.
- Multiple methods were employed to boost compliance, including appointment reminders, transport assistance, and reduced wait times.
- Continuity of care, family involvement, and physician communication were also utilized.
Main Results:
- A high visit adherence rate of 93.9% was achieved within the specified timeframes.
- Only 3.9% of patients were classified as dropouts, with 12 individuals lost to follow-up.
- Adherence rates in BHAT appeared slightly higher than in comparable secondary prevention trials.
Conclusions:
- Proactive strategies effectively enhance patient visit adherence in large clinical trials for post-MI patients.
- The BHAT achieved excellent adherence, suggesting the effectiveness of multifaceted compliance-enhancing interventions.
- Findings support the importance of objective adherence measures in evaluating the success of secondary prevention trials.
Abstract:
Efforts were made in the Beta Blocker Heart Trial (BHAT), a double-blind study of 3837 post-MI patients, to enhance visit adherence, a measure of compliance that is not subjective and can be easily monitored. Of the required visits, 93.9% were completed in the window, 3.9% of the patients were classified as dropouts and 12 persons were lost to follow-up. Methods used to enhance compliance varied with circumstances but included appointment reminders, assistance with transportation, minimal waiting times, newsletters, continuity of care, involvement of family members, and close contact with private physicians. Comparisons of the BHAT visit adherence rates to those from other clinical trials are difficult to make because there are few reports in the literature regarding follow-up in large multicenter clinical trials. However, data obtained through personal communications, as well as published reports, indicate that adherence in primary prevention trials was generally less than that of secondary prevention trials. Adherence rates in the BHAT tended to be slightly higher than those of comparable trials.